Skip to content
value.today

Vivus

VVUSUnlisted company
$29 Mlast known market cap, Jan 2020 — no current value
Compare
World rank
—
no current market cap
Revenue
$70 M
For year ending December-2019
Net income
$-32 M
-45.2% margin
SEC filing
Employees
—

Vivus in brief

Vivus is an unlisted company in the Biotechnology industry, based in Mountain View, USA. It was founded in 1991. In the year to December 2019 it had sales of $70 M and a net loss of $32 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Vivus

Vivus (OTCID Basic: VVUSQ) is a small pharmaceutical company headquartered in Campbell, California that specializes in obesity, sleep, and sexual health. Vivus developed Avanafil, an erectile dysfunction drug that has completed Phase 3 clinical trials. The drug has been approved for use by the Food and Drug Administration, and is sold under the trademark name Stendra. Stendra is the first and only oral erectile dysfunction treatment approved to be taken approximately 15 minutes before sexual activity.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Vivus timeline

2 events, 1991–1996
  1. 1991
  2. 🏁
    · approximate
    Founded
  3. 1996
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of Vivus from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Vivus

Acquisitions and changes
Delisted: it ended its SEC registration (Form 15) on 8 January 2021.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-45.2%
Operating margin
-15.7%
Return on equity
—
Liabilities / assets
131.7%
Net debt
$209M
Revenue growth
+7.2%
R&D / revenue
15.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2012: revenue —, net income $-140M—FY12Fiscal year ending Dec 2013: revenue $81M, net income $-174M$81MFY13Fiscal year ending Dec 2014: revenue $114M, net income $-83M$114MFY14Fiscal year ending Dec 2015: revenue $95M, net income $-93M$95MFY15Fiscal year ending Dec 2016: revenue $124M, net income $23M$124MFY16Fiscal year ending Dec 2017: revenue $65M, net income $-31M$65MFY17Fiscal year ending Dec 2018: revenue $65M, net income $-37M$65MFY18Fiscal year ending Dec 2019: revenue $70M, net income $-32M$70MFY19
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2019$70M+7.2%$-11M$-32M-45.2%
Dec 2018$65M-0.5%$-3M$-37M-56.8%
Dec 2017$65M-47.4%$3M$-31M-46.7%
Dec 2016$124M+30.2%$56M$23M18.8%
Dec 2015$95M-16.4%$-60M$-93M-97.6%
Dec 2014$114M+40.8%$-51M$-83M-72.4%
Dec 2013$81M—$-155M$-174M-215.2%
Dec 2012——$-140M$-140M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2019$-30M$0M$-31M$-2.96—
Dec 2018$-24M$0M$-24M$-3.48—
Dec 2017$-16M$0M$-16M$-2.89—
Dec 2016$38M$0M$38M$2.22—
Dec 2015$-46M$0M$-47M$-0.90—
Dec 2014$-38M$0M$-38M$-0.80—
Dec 2013$-135M$2M$-137M$-1.72—
Dec 2012$-132M$2M$-134M$-1.42—

SEC filings

Official filings of Vivus with the US Securities and Exchange Commission.

Annual results

Revenue
$70 M
Operating income
$-11 M
Net income
$-32 M

For year ending December-2019 · source: SEC filing

Balance sheet

Total assets
$218 M
Total liabilities
$288 M
Total equity
$-69 M

As of December-2019

Insider trading at Vivus#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
34
since
Vivus: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Santosh T. VargheseChief Medical OfficerGrant or award+700$2.380$2 K9,242Form 4
filed Mark K. OkiSVP, CFO, CAOGrant or award+700$2.380$2 K12,100Form 4
filed Mark K. OkiSVP, CFO, CAOGrant or award+700$2.840$2 K11,400Form 4
filed Santosh T. VargheseChief Medical OfficerGrant or award+700$2.840$2 K8,542Form 4
filed John P. AmosChief Executive Officer, DirectorBuyamended+11,000$4.850$53 K181,850Form 4/A
filed John P. AmosChief Executive Officer, DirectorBuy+11,000$4.850$53 K1.72 MForm 4
filed Eric W. RobertsDirectorBuy+8,500$4.820$41 K16,660Form 4
filed Santosh T. VargheseChief Medical OfficerGrant or award+700$2.710$2 K7,842Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Vivus#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Stock splits: 10-for-1 split

Bankruptcy filing: (8-K)

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Vivus scorecard#

Passes 3 of the 13 checks that could be worked out: strongest in growth (2 of 6), weakest in financial health (0 of 3). Fiscal year 2019.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth2 of 6
    • ✓Revenue grew in the newest year7.2%Revenue up 7.2% in fiscal 2019.
    • ✗Revenue up more than 5% a year over three years-17.5%-17.5% a year over the three years to fiscal 2019.
    • ✗Faster growth over three years than its peers' median-17.5%-17.5% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-2.96 vs -3.48Diluted EPS -2.96 in fiscal 2019 against -3.48 the year before (report's currency).
    • ✓Net income higher than five years earlier-$32 M-$32 M in fiscal 2019 against -$83 M in 2014.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2019.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$32 MNet income -$32 M in fiscal 2019.
    • ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2019.
    • ✓Operating margin above its peers' median-15.7%-15.7% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✗Operating margin wider than three years earlier-15.7%-15.7% in fiscal 2019 against 44.8% in 2016.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.43 at the end of fiscal 2019.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • ✗Net debt below three years of EBITDA56.0×Net debt 56.0 times EBITDA in fiscal 2019.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2019.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Vivus: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Vivus: statements by fiscal year
PeriodTrendFY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014FY 2013to Dec 31, 2013FY 2012to Dec 31, 2012FY 2011to Dec 31, 2011FY 2010to Dec 31, 2010
Income statement
Revenue70656512495114812.0——
Cost of revenue161517r9.9r34334.90.2——
Research and development107.35.35.6101430322540
Selling, general and administrative—3840527911215811022—
Selling and marketing181417———————
General and administrative222423————1102226
Operating expenses—6963691561652361424766
Total costs and expenses816963———————
Operating income−11−3.52.856−60−51−155−140−47−66
Interest and finance income———————0.20.2r0.5
Interest expense and finance costs————————0.04.3
Net interest income—————−33−200.20.2—
Other non-operating income (expense)−21−33−33−32−33−33−200.20.2−9.8
Income before tax−31−37−3123−93−83−175−140−47−75
Income tax0.00.10.00.10.0−0.60.10.00.20.0
Income from continuing operations−32−37−3123−93−83−175−140−47−75
Income from discontinued operations——————0.5−0.10.99.4
Net income attributable to shareholders−32−37−3123−93−83−174−140−46−66
Earnings per share, basic-2.96-3.48-2.89r2.23r-0.90-0.80-1.72-1.42-0.55-0.82
Earnings per share, diluted-2.96-3.48-2.89r2.22r-0.90-0.80-1.72-1.42-0.55-0.82
Shares, weighted average (basic)—1111r10r104103—988481
Shares, weighted average (diluted)111111r10r104103101988481
Balance sheet
Cash and cash equivalents333066859583103594037
Short-term investments081160185146216————
Receivables2226129.59.012122.8——
Inventory34231816143449253.13.2
Other current assets8.17.57.28.39.4r132019r1.81.6
Current assets97168263303274r358424262r152144
Property, plant and equipment0.20.30.50.81.01.32.02.00.30.2
Right-of-use (leased) assets0.8—————————
Other intangible assets120134————————
Non-current assets—————7.25.90.3——
Total assets218302265306277r367432264152144
Accounts payable7.78.9104.77.11011252.92.4
Debt due within a year183—5.18.714r100———
Current liabilities22543394859r57r52411112
Long-term debt59294231233217r217213———
Lease liabilities (non-current)0.5—————————
Total liabilities288342274288284r28427841——
Retained earnings−912−881−844−813−836−743−661−486−346−300
Shareholders' equity−69−40−9.318−7.183153223141132
Total equity—————————132
Total liabilities and equity218302265306277r367432264152144
Shares outstanding111111r1051041041031018982
Cash-flow statement
Depreciation and amortization158.90.81.11.41.1————
Share-based compensation2.03.32.92.33.69.832167.46.4
Cash from operating activities−30−24−1638−46−38−135−132r−37r−64r
Capital expenditure−0.0−0.0−0.0−0.2−0.3−0.3−1.8−1.7−0.2−0.1
Cash from investing activities82−5624−406716−90−55r−8.6r85r
Cash from financing activities−4944−26−8.7−8.92.127020648−24
Exchange-rate effect on cash−0.0—————————
Change in cash2.2−36−18−1112−2045192.3−3.3
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Mar 31, 2020. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Vivus#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Bankruptcy or receivership 1 · Delisting notice 1 · Debt called early 2 · Directors and officers 5 · Material agreement 7 · Shareholder rights changed 1 · Results announced 6

Vivus: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Bankruptcy or receivershipDebt called earlyDirectors and officersMaterial agreement8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Debt called earlyMaterial agreement8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Material agreementShareholder rights changed8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officersMaterial agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Jul 13, 2020

Layoffs at Vivus#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
20
2013–2013
Latest
20 people
2013-10-30
Vivus: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2013·········20··20
Vivus: latest layoffs
AnnouncedPeopleKindWhereSource
20 peopleRestructuring planSEC 8-K“Costs Associated with Exit or Disposal Activities On October 30, 2013, as part of the Company’s ongoing efforts to reduce costs by eliminating expenses that are not essential to ex…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Vivus compares in Biotechnology

  • Revenue$70 M · higher than 64% of 647
  • Net margin-45.1% · higher than 52% of 408
  • Revenue growth7.2% · higher than 50% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Vivus🇺🇸$29 M—-45.1%+7.2%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 1, 2020 (last known)
Annual results:
For year ending December-2019
Balance sheet:
As of December-2019
Profile updated:
Nov 16, 2026

Figures from SEC filing, Wikidata, Wikipedia, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Vivus? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Vivus's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Vivus? Suggest a correction